A second look at the pT1 G3 bladder tumour.

Area of Science:

• Uro-oncology
• Cancer research
• Clinical trials

Background:

• pT1 G3 bladder cancer presents a high risk of tumor progression and mortality.
• Intravesical Bacillus Calmette-Guerin (BCG) is used for superficial bladder cancer, with extrapolated use in pT1 G3 cases.
• Adjuvant intravesical BCG after transurethral resection (TUR) shows mixed results in reducing progression for pT1 G3 bladder cancer.

Purpose of the Study:

• To evaluate the effectiveness of intravesical Bacillus Calmette-Guerin (BCG) in managing pT1 G3 bladder cancer.
• To review existing data on adjuvant treatments for high-risk bladder cancer.
• To identify potential prognostic indicators for tumor progression in pT1 G3 bladder cancer.

Main Methods:

• Review of Phase II studies on adjuvant intravesical BCG post-TUR for pT1 G3 bladder cancer.
• Analysis of a randomized study on adjuvant radiotherapy for pT1 G3 bladder cancer.
• Assessment of early cystectomy outcomes for high-risk cases.

Main Results:

• Phase II studies suggest a potential benefit of intravesical BCG, but data are inconsistent.
• Adjuvant radiotherapy did not demonstrate a significant benefit, with high progression rates persisting.
• Early cystectomy results are often disappointing, possibly due to patient selection issues.

Conclusions:

• The efficacy of intravesical BCG for pT1 G3 bladder cancer requires further investigation due to mixed results.
• Identifying patients at exceptionally high risk of progression remains a clinical challenge.
• Tumor size, carcinoma in situ, and early recurrence may be prognostic factors, but require more data.